国产精品色午夜小视频,99久久无码一区人妻a黑

SU-DHL-10 人彌漫大B 返回列表頁(yè)

參考價(jià)

面議

具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號(hào)

品牌

廠商性質(zhì)生產(chǎn)商

所在地

在線詢價(jià) 加入對(duì)比查看聯(lián)系電話

更新時(shí)間：2025-02-11 15:24:41瀏覽次數(shù)：13次

聯(lián)系我時(shí)，請(qǐng)告知來(lái)自化工儀器網(wǎng)

產(chǎn)品名稱(chēng)：SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞、SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞、SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞、SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞；

人B細(xì)胞淋巴瘤細(xì)胞 SU-DHL-10

種屬	人
別稱(chēng)	Su-DHL-10; SUDHL10; Sudhl10; SUDHL-10; SuDHL 10; Stanford University-Diffuse Histiocytic Lymphoma-10; DHL10
組織來(lái)源	淋巴結(jié)
疾病	大細(xì)胞淋巴瘤
傳代比例/細(xì)胞消化	1：2傳代
培養(yǎng)基配置	RPMI1640 培養(yǎng)基；10%胎牛血清；1%雙抗
簡(jiǎn)介	established from the pleural effusion of a 25-year-old man with B-cell non-Hodgkin lymphoma (B- NHL), described at the time as diffuse histiocytic lymphoma; cell line carries EZH2 Y641F mutation (own results); assigned to GCB-like lymphoma subtype (germinal center B-cell)
形態(tài)	淋巴母細(xì)胞樣
生長(zhǎng)特征	懸浮生長(zhǎng)
倍增時(shí)間	~40h
STR	D5S818: 11, 12 D13S317: 10, 11 D7S820: 8, 11 D16S539: 10, 11 vWA: 17 THO1: 8, 9.3 TPOX: 8 CSF1PO: 10, 13 Amelogenin: XYTPOX: 8 CSF1PO: 10, 13
培養(yǎng)條件	氣相：空氣，95% ；二氧化碳，5%。溫度：37攝氏度，培養(yǎng)箱濕度為70%-80%。
凍存條件	凍存液：90%FBS ，DMSO 10%, 或使用非程序凍存液：貨號(hào)JY-H040
保藏機(jī)構(gòu)	ATCC; CRL-2963
備注	該細(xì)胞為懸浮細(xì)胞，請(qǐng)注意離心收集細(xì)胞懸液，請(qǐng)勿直接倒掉細(xì)胞培養(yǎng)液。
產(chǎn)品使用	于科學(xué)研究，不可作為動(dòng)物或人類(lèi)疾病的治療產(chǎn)品使用。

with fewer side effects, and with better therapeutic results. In addition, medicines that target tau proteins in addition to Aβ are in the works. Early intervention, based on precise biomarkers, is a linchpin of Alzheimers care, emphasizing the critical need for detecting the disease at its earliest stages. Lifestyle interventions, encompassing diet, exercise, cognitive training, and social engagement, are emerging as key components in the fight against cognitive decline. Data analytics and art are gaining prominence as strategies to mitigate the brains inflammatory responses. To pool knowledge and resources in the fight against Alzheimers, international cooperation between scientists, doctors, and pharmaceutical companies is still essential. In essence, a complex, individualized, and collaborative strategy will characterize Alzheimers research and therapy in the future. Despite obstacles, these encouraging possibilities show the ongoing commitment of the scientific and medical communities to combat A.D. head-on, providing a glimmer of hope to the countless people and families touched by this savage sickness.